Ikaros isoforms and mutants
AssigneeParker Hughes Institute
InventorsFatih M. Uckun, Mya L. Crotty
Life of this patent
Estimating the term…
Abstract
Specific Ikaros mutations, as well as the correlation of the presence of the specific Ikaros mutations and other wild-type non-DNA binding Ikaros isoforms with lymphoid cell abnormality is provided in the in the invention. Methods for detecting and treating lymphoid cell abnormality, including hematologic malignancy, are also provided.
Claims25
A nucleic acid sequence encoding at least a portion of an Ikaros protein and comprising the sequence of one or more of SEQ ID NO:
- 24, SEQ ID NO:
- 25;
- SEQ ID NO:
- 10, and SEQ ID NO:
- 26.
A method for the detection of abnormal lymphohematopoietic cells, comprising analyzing a sample of lymphoid cells for the presence of aberrantly spliced Ikaros isoforms.
A method for the detection of hematologic malignancy, the method comprising:
- analyzing a sample of hematologic cells for expression of Ikaros protein isoforms;
- and correlating the expression of dominant negative Ikaros isoforms with hematologic malignancy.
A method for the treatment of hematologic malignancy, said method comprising expressing in hematologic cells an increased amount of Ik-1 or Ik-2, said expression increased as compared with a non-treated control.
A method for the diagnosis of cancer cells, comprising analyzing a cell sample for expression of non-DNA binding Ikaros protein isoforms;
- and correlating the expression of non-DNA binding Ikaros isoforms with hematologic malignancy.
(New) A method of treating a hematological cell having a lymphoid disease characterized by a reduced amount of Ikaros-1, Ikaros-2, Ikaros-3, or some combination thereof in the hematological cell as compared with a normal hematological cell comprising administering Ikaros-1, Ikaros-2, Ikaros-3, or some combination thereof to the hematological cell.
Dependencies are inferred from the claim text.